Rene Louapre, MD
Internal Medicine · New Orleans, LANPI 1417957002
Payments from drug & device makers
Across 295 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$672
- GSK$623
- Pfizer$539
- Novo Nordisk$432
- AstraZeneca$338
- Bayer$327
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,589100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 43 | $672 |
| GSK | 43 | $623 |
| Pfizer | 34 | $539 |
| Novo Nordisk | 31 | $432 |
| AstraZeneca(2 entities) | 22 | $338 |
| Bayer | 20 | $327 |
| AbbVie(2 entities) | 14 | $269 |
| Boehringer Ingelheim | 13 | $199 |
| Sanofi-aventis U.S. LLC | 8 | $145 |
| Astellas Pharma US Inc | 9 | $143 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $119 |
| Amarin Pharma, Inc. | 7 | $113 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $109 |
| E.r. Squibb & Sons, L.L.C. | 7 | $107 |
| Amgen | 5 | $82 |
| Abbott | 3 | $60 |
| Exact Sciences | 3 | $53 |
| Johnson & Johnson | 3 | $45 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Novartis | 2 | $30 |
| Merck | 2 | $25 |
| Viiv Healthcare Company | 1 | $19 |
| Boston Scientific | 1 | $17 |
| Seqirus USA Inc | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Shire North American Group Inc | 1 | $13 |
How this compares
$4,589 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 125 | $116,927 |
| OzempicSemaglutide | 96 | $110,650 |
| MounjaroTirzepatide | 86 | $103,131 |
| JardianceEmpagliflozin | 112 | $97,843 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $74,846 |
| TivicayDolutegravir Sodium | 24 | $62,436 |
| DescovyEmtricitabine/Tenofov Alafenam | 24 | $61,501 |
| JanuviaSitagliptin Phosphate | 55 | $59,381 |
| TrulicityDulaglutide | 49 | $58,282 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $34,566 |
| PrezcobixDarunavir/Cobicistat | 12 | $34,273 |
| Tresiba Flextouch U-100Insulin Degludec | 69 | $30,707 |
| FarxigaDapagliflozin Propanediol | 34 | $27,668 |
| LinzessLinaclotide | 41 | $25,093 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 46 | $22,023 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $672 | $161,413135 claims |
| Novo NordiskOzempic, Rybelsus | $432 | $127,754110 claims |
| PfizerEliquis, Premarin | $539 | $122,338152 claims |
| Boehringer IngelheimJardiance, Tradjenta | $199 | $118,169132 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $623 | $70,177111 claims |
| MerckJanuvia, Janumet Xr | $25 | $62,87267 claims |
| Viiv Healthcare CompanyTivicay | $19 | $62,43624 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $45 | $54,57826 claims |
| AstraZenecaFarxiga, Symbicort | $338 | $35,94867 claims |
| AbbVieLinzess, Synthroid | $269 | $27,79870 claims |
| NovartisEntresto | $30 | $17,11617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in New Orleans
- William SmithNew Orleans$50.5M
- Brian LewisNew Orleans$2M
- Steven DeitelzweigNew Orleans$939K
- Lydia BazzanoNew Orleans$892K
- Eboni Price-HaywoodNew Orleans$659K
- Susan Lewis AbdalianNew Orleans$301K
- Eduardo RodriguezNew Orleans$167K
- Shigeki SaitoNew Orleans$120K
- Jonathan GugelNew Orleans$95K
- Keith WinfreyNew Orleans$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.